Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01404936 · ClinicalTrials.gov registry record · Phase 2
Study of a-Interferon With Adriamycin, Bleomycin, Velban, and Dacarbazine (ABVD) With Hodgkin's Disease
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
NCT01404936: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT01404936 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 35 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01404936, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
Study Summary
This is a clinical research study of interferon (IFN) plus chemotherapy with the standard combination of Adriamycin, Bleomycin, Velban, and Dacarbazine (ABVD). The treatment will be given to patients with Hodgkin's disease. The study will look at whether adding IFN to ABVD improves the immune response against Hodgkin's disease, and will determine whether the toxicity of ABVD is increased by adding IFN.
Interventions
- DRUG Dacarbazine
- DRUG Bleomycin
- DRUG Adriamycin
- DRUG Interferon-2A
- DRUG Velban
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 1996-07 |
| Est. Completion | 2011-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01404936
The ClinicalTrials.gov registry entry for NCT01404936 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Dacarbazine is the first listed.
NCT01404936 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01404936 about?
NCT01404936 is a clinical study titled "Study of a-Interferon With Adriamycin, Bleomycin, Velban, and Dacarbazine (ABVD) With Hodgkin's Disease". This is a clinical research study of interferon (IFN) plus chemotherapy with the standard combination of Adriamycin, Bleomycin, Velban, and Dacarbazine (ABVD). The treatment will be given to patients with Hodgkin's disease. The study will look at whether adding IFN to ABVD improves the immune respon...
What is the current status of trial NCT01404936?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 1996-07. Estimated completion is 2011-12.
What interventions are being tested in trial NCT01404936?
The interventions under investigation include: Dacarbazine (DRUG), Bleomycin (DRUG), Adriamycin (DRUG), Interferon-2A (DRUG), Velban (DRUG).
Who is sponsoring clinical trial NCT01404936?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.